Christian Ottensmeier

Professor of Immuno-Oncology

University of Liverpool

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Christian Ottensmeier is a Professor of Immuno-Oncology at the University of Liverpool, UK. His research focuses on the advancement of therapeutic strategies in cancer treatment, particularly non-small cell lung cancer and mesothelioma. Recent publications highlight his work on antibody-based imaging technologies, the efficacy of immunotherapy, and the genetic factors influencing immune responses in cancer therapies.

Articles (11)

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (15)

Ricky Thakrar

UNITED KINGDOM

Christian Ottensmeier

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies

CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.

Using DNA sequencing data to quantify T cell fraction and therapy response

Early-Phase Interventional Trials in Oral Cancer Prevention.

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms

COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types

The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer.

Collaborators (15)

Ricky Thakrar

Ferhat Ay

Alfredo Addeo

David J. Pinato

David Pearce

Caroline McCarthy

Gurdeep Sagoo

Fiona Byrne

Benjamin J Schmiedel

Diana Johnson

Valeria Maffeis

peter parker

Alessio Signori

Gary Middleton

Meenali Chitnis

Make your next move.